Biotech Firm Cuts Production Costs by Seventy Percent Ahead of Commercial Launch

Biotech Firm Cuts Production Costs by Seventy Percent Ahead of Commercial Launch

2026-11-20 companies

New York, Thursday, 19 November 2026.
eXoZymes slashed manufacturing costs for its lead compound below $1,000 per kilogram, securing commercial partner Curia despite posting a $2.24 million third-quarter loss and managing $3.26 million in cash.

eXoZymes Achieves Breakthrough Cost Reduction in Nutraceutical Manufacturing

Biotechnology firm eXoZymes Inc. (NASDAQ: EXOZ) has achieved a significant milestone in its commercialization roadmap, reducing manufacturing costs for its lead compound NCT to below $1,000 per kilogram from initial estimates of $3,500 per kilogram [1][2][5]. This represents a cost reduction of approximately 71.429% [alert! ‘calculation based on sources 1, 2, and 5’]. The breakthrough comes as the company prepares for large-scale production of its nutraceutical products, including the human supplement Tyferyn, which utilizes the company’s AI-enhanced enzyme platform. eXoZymes selected Curia as its commercial-scale manufacturing partner in September 2026, with technology transfer beginning in Q4 2026 [1][2][5].

Third Quarter Results Reflect Investment Phase Amid Cost Progress

Despite posting a $2.24 million net loss for Q3 2026 (including a $0.77 million non-cash gain from warrant liabilities), eXoZymes demonstrated operational progress in reducing production costs and securing manufacturing partnerships [1]. The company reported operating expenses of $3.05 million for the quarter, up from $2.52 million in Q3 2025, reflecting ongoing investment in its platform development and commercialization efforts [1]. As of September 30, 2026, eXoZymes held $3.26 million in cash and cash equivalents, which management indicated should support operations through the beginning of 2027 [1]. The net loss for the nine months ended September 30, 2026, totaled $7.49 million [1].

Strategic Partnership with Curia Accelerates Commercial Timeline

The selection of Curia as eXoZymes’ commercial-scale manufacturing partner marks a critical step in the company’s transition from development to production [1][2][5]. The partnership aims to support the large-scale manufacturing of NCT, the rare natural molecule at the core of eXoZymes’ Tyferyn supplement brand [1][2]. CEO Michael Heltzen emphasized the significance of this milestone, stating that the company is entering an exciting new phase as it advances toward commercial manufacturing while expanding its pipeline of high-value molecules [1]. The collaboration with Curia is expected to enable eXoZymes to meet anticipated demand for its nutraceutical products while maintaining cost competitiveness [1][2][5].

Financial Backdrop and Market Context

eXoZymes’ progress occurs against a backdrop of broader market challenges in the biotechnology sector. The company’s majority owner, MDB Capital Holdings (NASDAQ: MDBH), reported a Q3 2026 net loss of $16 million, driven in part by a $9.9 million reduction in the value of its 42% stake in eXoZymes [2]. MDB Capital’s cash reserves declined to $8.3 million as of Q3 2026, from $13.2 million at the end of 2025 [2]. Despite these challenges, MDB Capital’s fee income increased 96% year-over-year to $4.2 million for the first nine months of 2026, with $892,000 in fees originating from eXoZymes [2][3][4][5]. Management has indicated plans to distribute assets to shareholders in 2027 as portfolio companies reach inflection points [2][3][4][5].

Technological Innovation Drives Competitive Advantage

eXoZymes’ cost reduction achievements stem from its proprietary cell-free biomanufacturing platform, which combines AI-enhanced enzyme design with advanced manufacturing techniques [GPT]. The company’s ability to achieve a 100-fold scale-up of its lead compound NCT in a 100-liter pilot run in January 2026 demonstrates the scalability of its platform [4]. This technological edge positions eXoZymes to compete effectively in the nutraceutical market, where manufacturing efficiency and product quality are critical differentiators [GPT]. The company’s pipeline includes additional compounds such as cannabinoid analogs and santalene, reflecting its broader ambitions in high-value biochemical markets [1].

Investor Webinar Highlights Path Forward

eXoZymes hosted an investor webinar on November 19, 2026, at 5:00 PM Eastern Time, where CEO Michael Heltzen outlined the company’s progress and future plans [1]. During the briefing, Heltzen emphasized the company’s rapid progression from discovery to scalable production, a capability he described as setting eXoZymes’ platform apart in the industry [1]. The webinar provided investors with an opportunity to assess the company’s commercialization roadmap and evaluate the potential impact of its cost reductions and manufacturing partnerships. While the company’s financial results reflect its current investment phase, the technological and operational milestones achieved in 2026 suggest a strong foundation for future growth [1][2][5].

Sources


Biotechnology Earnings report